Enhanced multicancer screening assay through whole-genome methylation sequencing-based multimodal cell-free DNA analysis
A blood test combining multiple detection methods catches over 92% of cancers at early stages with very few false alarms, advancing noninvasive screening.
A multimodal cfDNA assay combining whole-genome methylation sequencing with fragmentomic features achieved 93.2% sensitivity and 95% specificity for multi-cancer detection in 1415 samples, including 92.3% sensitivity at stage I. This represents a substantial advance in liquid biopsy-based multicancer early detection technology.
What the study was
- Study design
- Validation study (multi-cancer screening)
- Population
- Multi-cancer and healthy control samples (8 primary cancer types)
- Sample size
- 1415
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Experimental and Molecular Medicine
Why it surfaced
Exp Mol Med; n=1415; 8 cancer types; 93.2% sensitivity/95% specificity; stage I sensitivity 92.3% — exceptional performance for multicancer early detection; deferred from 2026-04-22 run due to abstract parse failure, now resolved.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.